570 related articles for article (PubMed ID: 29765039)
21. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
[TBL] [Abstract][Full Text] [Related]
23. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
[TBL] [Abstract][Full Text] [Related]
24. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling.
Kim IG; Kim SY; Choi SI; Lee JH; Kim KC; Cho EW
Oncogene; 2014 Jul; 33(30):3908-17. PubMed ID: 24013232
[TBL] [Abstract][Full Text] [Related]
25. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
26. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
27. The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
Deng R; Zuo C; Li Y; Xue B; Xun Z; Guo Y; Wang X; Xu Y; Tian R; Chen S; Liu Q; Chen J; Wang J; Huang X; Li H; Guo M; Wang X; Yang M; Wu Z; Wang J; Ma J; Hu J; Li G; Tang S; Tu Z; Ji H; Zhu H
Cell Mol Immunol; 2020 Nov; 17(11):1163-1179. PubMed ID: 32963356
[TBL] [Abstract][Full Text] [Related]
28. Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses.
Zhang Y; Morgan R; Chen C; Cai Y; Clark E; Khan WN; Shin SU; Cho HM; Al Bayati A; Pimentel A; Rosenblatt JD
Int Immunol; 2016 Sep; 28(9):423-33. PubMed ID: 26895637
[TBL] [Abstract][Full Text] [Related]
29. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
30. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
[TBL] [Abstract][Full Text] [Related]
31. HIF-1α induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway.
Yang SW; Zhang ZG; Hao YX; Zhao YL; Qian F; Shi Y; Li PA; Liu CY; Yu PW
Oncotarget; 2017 Feb; 8(6):9535-9545. PubMed ID: 28076840
[TBL] [Abstract][Full Text] [Related]
32. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
[TBL] [Abstract][Full Text] [Related]
33. Diverse Targets of β-Catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse.
Chang YW; Su YJ; Hsiao M; Wei KC; Lin WH; Liang CL; Chen SC; Lee JL
Cancer Res; 2015 Aug; 75(16):3398-410. PubMed ID: 26122848
[TBL] [Abstract][Full Text] [Related]
34. Regulation of PD-L1 Expression by NF-κB in Cancer.
Antonangeli F; Natalini A; Garassino MC; Sica A; Santoni A; Di Rosa F
Front Immunol; 2020; 11():584626. PubMed ID: 33324403
[TBL] [Abstract][Full Text] [Related]
35. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Cha JH; Yang WH; Xia W; Wei Y; Chan LC; Lim SO; Li CW; Kim T; Chang SS; Lee HH; Hsu JL; Wang HL; Kuo CW; Chang WC; Hadad S; Purdie CA; McCoy AM; Cai S; Tu Y; Litton JK; Mittendorf EA; Moulder SL; Symmans WF; Thompson AM; Piwnica-Worms H; Chen CH; Khoo KH; Hung MC
Mol Cell; 2018 Aug; 71(4):606-620.e7. PubMed ID: 30118680
[TBL] [Abstract][Full Text] [Related]
36. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
[No Abstract] [Full Text] [Related]
37. LIN28/
Chen Y; Xie C; Zheng X; Nie X; Wang Z; Liu H; Zhao Y
Cancer Immunol Res; 2019 Mar; 7(3):487-497. PubMed ID: 30651289
[TBL] [Abstract][Full Text] [Related]
38. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
39. TGFβ1-induced down-regulation of microRNA-138 contributes to epithelial-mesenchymal transition in primary lung cancer cells.
Zhang F; Li T; Han L; Qin P; Wu Z; Xu B; Gao Q; Song Y
Biochem Biophys Res Commun; 2018 Feb; 496(4):1169-1175. PubMed ID: 29407170
[TBL] [Abstract][Full Text] [Related]
40. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
